Treats myasthenia gravis. ANDA 204737, held by Alvogen. Pyridostigmine Bromide.
As of Nov 16, 2026, ANDA 204737 (Pyridostigmine Bromide), held by Alvogen, was first approved by FDA on Jun 26, 2015, with 0 approved supplements and 0 published complete response letters.
INDICATION Pyridostigmine Bromide Extended-release Tablets is useful in the treatment of myasthenia gravis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 26, 2015 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pyridostigmine Bromide180MG · tablet, extended release;oral | Pyridostigmine Bromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters